GlaxoSmithKline Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline or view top-rated stocks.

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for GlaxoSmithKline.

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by $0.02. The pharmaceutical company had revenue of $8.74 billion for the quarter, compared to analysts' expectations of $8.71 billion. GlaxoSmithKline had a net margin of 18.50% and a trailing twelve-month return on equity of 29.60%. The firm's quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.39 EPS.
View GlaxoSmithKline's earnings history.

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 5.5% and is now trading at $37.69.
View which stocks have been most impacted by COVID-19.

GlaxoSmithKline announced a quarterly dividend on Thursday, February 4th. Stockholders of record on Friday, February 19th will be paid a dividend of $0.628 per share on Thursday, April 8th. This represents a $2.51 dividend on an annualized basis and a dividend yield of 6.66%. The ex-dividend date is Thursday, February 18th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.50.
View GlaxoSmithKline's dividend history.

GlaxoSmithKline pays an annual dividend of $2.52 per share and currently has a dividend yield of 6.97%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strock track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 79.50%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, GlaxoSmithKline will have a dividend payout ratio of 81.82% in the coming year. This indicates that GlaxoSmithKline may not be able to sustain their current dividend.
View GlaxoSmithKline's dividend history.

Some companies that are related to GlaxoSmithKline include Roche (RHHBY), Abbott Laboratories (ABT), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), CSL (CSLLY), Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY) and Vertex Pharmaceuticals (VRTX).
View all of GSK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline's stock is owned by many different institutional and retail investors. Top institutional investors include Welch & Forbes LLC (0.02%), Jacobs & Co. CA (0.01%), Farmers Trust Co. (0.01%), Pacer Advisors Inc. (0.00%), Signature Wealth Management Group (0.00%) and Old Port Advisors (0.00%).
View institutional ownership trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Ipswich Investment Management Co. Inc., City Holding Co., Crossmark Global Holdings Inc., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Chemung Canal Trust Co., Pacer Advisors Inc., First Bank & Trust, and Optimum Investment Advisors.
View insider buying and selling activity for GlaxoSmithKline or view top insider-selling stocks.

GSK stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, Boothe Investment Group Inc., Marotta Asset Management, Jacobs & Co. CA, Ballew Advisors Inc, Hohimer Wealth Management LLC, KG&L Capital Management LLC, and Farmers Trust Co..
View insider buying and selling activity for GlaxoSmithKline or or view top insider-buying stocks.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GSK stock can currently be purchased for approximately $37.69.

GlaxoSmithKline has a market capitalization of $101.48 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis.

GlaxoSmithKline employs 99,437 workers across the globe.

GlaxoSmithKline was founded in 2000.

The official website for GlaxoSmithKline is www.gsk.com.

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]